SIMONELLI, Matteo
 Distribuzione geografica
Continente #
NA - Nord America 2382
EU - Europa 337
AF - Africa 117
AS - Asia 69
Continente sconosciuto - Info sul continente non disponibili 6
SA - Sud America 5
OC - Oceania 2
Totale 2918
Nazione #
US - Stati Uniti d'America 2346
NG - Nigeria 117
IT - Italia 113
FR - Francia 66
NL - Olanda 44
DE - Germania 39
CA - Canada 36
GB - Regno Unito 29
TR - Turchia 29
IL - Israele 19
BE - Belgio 15
FI - Finlandia 14
CN - Cina 9
CL - Cile 5
EU - Europa 4
CH - Svizzera 3
IR - Iran 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AU - Australia 2
ES - Italia 2
PL - Polonia 2
RU - Federazione Russa 2
AT - Austria 1
BG - Bulgaria 1
IN - India 1
JP - Giappone 1
KR - Corea 1
MD - Moldavia 1
NO - Norvegia 1
PH - Filippine 1
PT - Portogallo 1
RO - Romania 1
SE - Svezia 1
UA - Ucraina 1
Totale 2918
Città #
Wilmington 706
Chandler 449
San Mateo 299
Ann Arbor 189
Lawrence 127
Princeton 127
Leawood 119
Benin City 117
Woodbridge 81
Paris 66
Milan 64
Fairfield 60
Amsterdam 40
Toronto 35
Kocaeli 29
London 25
Boardman 22
San Diego 21
Seattle 21
Brussels 15
Helsinki 14
Norwalk 12
Abbiategrasso 8
Monmouth Junction 8
Des Moines 5
Nanjing 5
Redmond 5
Beijing 4
Redwood City 4
Zwolle 4
Cambridge 3
Clearwater 3
Raleigh 3
Taipei 3
Cupertino 2
Hanover 2
Phoenix 2
Poznan 2
Sacramento 2
Andover 1
Asbest 1
Ashburn 1
Augusta 1
Berlin 1
Borås 1
Buffalo 1
Chisinau 1
Genoa 1
Gorgonzola 1
Hockessin 1
Indianapolis 1
Jacksonville 1
Kemerovo 1
Köln 1
Leipzig 1
Manchester 1
Montréal 1
Pittsfield 1
Seoul 1
Torino 1
Valladolid 1
Totale 2725
Nome #
Response to Sunitinib in an Adult Patient With Rhabdoid Renal Cell Carcinoma 43
Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas 42
Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. 40
Targeted therapy for thymic epithelial tumors: a new horizon ? Review of the literature and two cases reports 39
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 39
Role of Myeloid Cells in the Immunosuppressive Microenvironment in Gliomas 37
Thymoma associated with myasthenia and autonomic anti-Hu paraneoplastic neuropathy 36
Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients’ management: close to clinic 36
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 36
Multimodal Characterization of Supratentorial Gliomas: Relationship Among Morphological, Metabolic and Molecular features 35
Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study 35
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors 34
FDG-PET as a tool to optimize residual surgery in patients with primary extragonadal germ cell tumors: preliminary results 34
Expression of the transcription factor HEY1 in glioblastoma: a preliminary clinical study 34
Infertility risk and teratogenicity of molecular targeted anticancer therapy: a challenging issue 33
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top" 33
Conducting Phase I Trials During the SARS-Coronavirus-2 Outbreak: About Science and Care 33
Correlation of microvascular fractal dimension with positron emission tomography [C-11]-methionine uptake in glioblastoma multiforme: Preliminary findings 32
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 32
Reproducibility of the WHO classification of thymomas: practical implications 32
Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in a observational study 31
COVID-19 and liver cancer clinical trials: not everything is lost 30
Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study. 30
Pathological characterization of nivolumab –related liver injury in a patient with glioblastoma 29
Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma 29
Neutrophils in Gliomas 29
Prognostic and predictive role of [F-18]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy 29
Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF 29
Value of Surgical Resection in Patients with Newly Diagnosed Grade III Glioma Treated in a Multimodal Approach: Surgery, Chemotherapy and Radiotherapy 29
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey 28
Electrolyte abnormalities and side effects of zoledronate in patients with bone metastases 28
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas 28
Imaging biomarkers in primary brain tumours 28
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 28
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme 28
Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma 27
Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin 27
VINORELBINE (V) IN PEMETREXED-PRETREATED PATIENTS (PTS) WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 27
HIGH-GRADE GLIOMAS AND IMMUNOTHERAPEUTIC EARLY PHASE CLINICAL TRIALS: A SINGLE-CENTER EXPERIENCE 27
Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series 27
The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing 27
Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome. 26
High-grade gliomas (HGGs) and immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience 26
The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma 26
Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives 26
Three-day low-dose Cisplatin administration in advanced non-small cell lung cancer (NSCLC): Efficacy and reduced toxicity 25
Advances in the biology of malignant pleural mesothelioma 25
Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis 25
Pharmacodynamic (PD) evaluation of soluble proteins from a phase I trial of lapatinib (L) in combination with sorafenib (S) 25
Vinorelbine as second or third-line therapy in pemetrexed-pretreated malignant pleural mesothelioma (MPM) patients 25
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study 25
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma 25
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma 24
Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment 24
Future developments in the management of malignant pleural mesothelioma 24
THE ROLE OF THYMIDTYLATE SYNTHASE (TS) AND EXCISION REPAIR CROSS-COMPLEMENTING GROUP 1 (ERCC1) IMMUNOHISTOCHEMICAL EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA (MPM) PATIENTS TREATED WITH PEMETREXED AND CARBOPLATIN 24
Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors 24
Insulin-Like Growth Factor-1 Receptor and Phosphorylated AKT-Serine 473 Expression in 132 Resected Thymomas and Thymic Carcinomas 24
Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution 23
Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma 23
Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC) 23
Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors 23
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 23
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 23
Editorial for "Noninvasive Assessment of MGMT Promoter Methylation Status in World Health Organization Grade II-IV Glioma Using Histogram Analysis of Inflow-Based Vascular-Space Occupancy Combined with Structural MR Imaging" 23
HYPOFRACTIONATED RADIATION THERAPY (OVER 3 WEEKS) CAN REPLACE CONVENTIONAL RADIATION THERAPY SCHEDULE (OVER 6 WEEKS) IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS? THE TIMES ARE RIPE 23
COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report 23
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal 23
Supratotal resection in newly diagnosed GBMs: role of this surgical strategy beyond enhancing boundaries 22
Outcome evaluation of patients with diagnosed WHO grade III glioma treated according to the molecular profile, the hystology, and the extent of resection (EOR) 22
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 22
Reliability of the HER2 status assessment by immunohistochemistry for breast cancer patients after preoperative chemotherapy 22
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors 22
Phase I, Pharmacokinetics (PK), Pharmacodynamic (PD) Study of Lapatinib (L) in Combination With Sorafenib (S) in Patients With Advanced Refractory Solid Tumours 22
High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review 22
Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient A CARE-compliant case report 22
Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience 21
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 21
IMPACT OF SOLUBLE TUMOR NECROSIS FACTOR-RECEPTORS (STNF-RS) SHEDDING ON OUTCOME IN PATIENTS TREATED WITH NGR-HTNF 21
PHASE I AND PHARMACODYNAMIC STUDY OF NGR-HTNF ADMINISTERED AT HIGH DOSES IN REFRACTORY PATIENTS WITH SOLID TUMORS 21
High incidence of hypocalcemia in patients with bone metastases from different kinds of neoplasms, treated with zoledronate 21
Phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) trial of NGR-hTNF given at high doses in patients with refractory solid tumors 21
Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial 21
Newly diagnoses grade III glioma patients: evaluation of factors conditioning outcome 21
Final results from ARQ 197-114: A phase 1b safety trial evaluating ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC) 21
Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis 21
Herpes infections in breast cancer patients treated with adjuvant chemotherapy 20
Optimizing residual surgery for patients with primary extragonadal germ cell tumors 20
IS SURGICAL RESECTION USEFUL IN ELDERLY NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS? OUTCOME EVALUATION AND PROGNOSTIC FACTORS ASSESMENT 20
Outcome of high-grade gliomas (HGGs) treated into immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience 20
Retreatment with pemetrexed-based chemotherapy (PBC) in patients with malignant pleural mesothelioma (MPM): An observational study 20
Phase 1 study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC): Correlation of tumor and serum biomarker data with disease control 20
PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB PLUS PEMETREXED AND CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 20
Phase I trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients with advanced nonsquamous non small cell lung cancer or malignant pleural mesothelioma 20
Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study 20
The role of thymidylate synthase (TS) and excision repair cross-complementing group 1 (ERCC1) immunohistochemical expression in malignant pleural mesothelioma patients treated with pemetrexed and carboplatin 20
Treatment of malignant pleural mesothelioma: current status and future directions 20
Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review. 20
Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO) 20
Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation 19
Totale 2628
Categoria #
all - tutte 16042
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16042


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202044 0000 00 00 00143
2020/20211426 4710198 11395 18499 28118517170
2021/2022689 32513139 46 28102 557119935
2022/2023881 28566162148 12099 10 0000
Totale 3040